BEAM - Hot Stocks: NTLA leads gene-editing stocks higher; ABUS rises on positive data; PERI raises guidance; QADA going private

TERADAT SANTIVIVUT/Moment via Getty Images Intellia Therapeutics (NTLA) led gene-editing stocks higher before the bell Monday. The company released positive data about a breakthrough gene-editing therapy. The news also boosted shares of Beam Therapeutics (BEAM), Editas Medicine (EDIT) and CRISPR Therapeutics (CRSP). Positive clinical results also helped shares of Arbutus Biopharma (ABUS). In other drug-related news, MannKind (MNKD) got a boost from a policy change from Medicare. Switching to another sector, Perion Network (PERI) rallied in the pre-market following the release of raised guidance. Meanwhile, QAD (QADA) received significant attention following a going-private deal valued at about $2B. Intellia Therapeutics skyrocketed more than 48% in Monday's pre-market action. The advance followed news that the company, along with Regeneron Pharmaceuticals (REGN), released the first-ever clinical data offering evidence for the safety and efficacy of in-vivo genome editing in humans using the CRISPR technology. The data from Intellia spurred gains throughout the

For further details see:

Hot Stocks: NTLA leads gene-editing stocks higher; ABUS rises on positive data; PERI raises guidance; QADA going private